Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market is expected to reach $9.5 billion by 2020, at a CAGR of 9% during the forecast period 2022-2028.

Castration-resistant prostate cancer (CRPC) or hormone refractory prostate cancer (CRPC) is a type of prostate cancer that recurs after administration of androgen deprivation therapy (ADT) and is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant rate owing to high unmet clinical needs, limited survival benefits, increasing prevalence and rapidly emerging therapeutic modifications. Market growth will revolve around new breakthrough therapies that are responsible for enjoying the survival benefits. Survival benefits play an important role in controlling the maximum sales and market penetration of approved new drugs.

Market Segments

By Therapy Type

• Chemotherapy
• Cytotoxic Agents
• Hormonal Therapy
• Anti-Androgens
• Immunotherapy
• Vaccines
• Radiotherapy
• Radio-Pharmaceuticals
• Global CRPC Market By Drug Delivery Method
• Oral Therapy
• Injectable Therapy

Key Players

Major market players such as Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, and others have been provided in the report.

Scope of the Report

The research study analyzes the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Report

1. What was the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.